sales@jinjingroup.com

  News Introduction

Vinpocetine(CAS 42971-09-5) treat neurological tinnitus and acute cerebral infarction

Date : 2016/10/9 11:11:29

Zhengzhou University Hospital, Zhengzhou Central Hospital researchers published papers to explore vinpocetine(CAS 42971-09-5) treatment of neurological tinnitus in clinical. Studies have shown that lidocaine combined with vinpocetine treatment of neurological tinnitus with satisfactory results. The article published in the "China Practical Medicine" 2014 the 28th issue.

80 cases of neurogenic tinnitus patients were randomly divided into treatment group and control group, 40 cases in each group. The treatment group was treated with lidocaine combined with vinpocetine, and the control group was treated with Salvia miltiorrhiza injection and Mecobalamin, 10 days as a course of treatment.

The total effective rate was 87.5% in the treatment group and 62.5% in the control group. The clinical symptoms of tinnitus were significantly better than those in the control group (P <0.05).

Qidong City Hospital of Neurology researchers published papers aimed at observing the vinpocetine(CAS 42971-09-5) injection and edaravone in the treatment of acute cerebral infarction clinical efficacy. Studies have shown that vinpocetine injection and edaravone in the treatment of acute cerebral infarction is safe and effective. The article published in the fifth of 2014 "Chinese Medicine" magazine.

70 cases of acute cerebral infarction patients were randomly divided into treatment group and control group of 35 cases. Two groups were given conventional treatment, the application of vinpocetine(CAS 42971-09-5) injection 20mg 250ml saline by intravenous infusion, 1 / d, the treatment group is also application of Edaravone injection 30mg 250ml saline intravenous infusion, 2 / D, 14d for a course of treatment. Neurological deficit scores were used to evaluate the efficacy of the two groups of patients.

The total effective rate of the treatment group was 88.57%, which was better than that of the control group (62.86%, P <0.01). No adverse reaction occurred during the treatment.